Publicacións (11) Publicacións de Sandra Moraña Fernández

2024

  1. Cardiometabolic effects of sacubitril/valsartan in a rat model of heart failure with preserved ejection fraction

    Biochemical Pharmacology, Vol. 230

  2. Effects of Sodium Nitroprusside on Lipopolysaccharide-Induced Inflammation and Disruption of Blood–Brain Barrier

    Cells, Vol. 13, Núm. 10

  3. Human recombinant relaxin-2 (serelaxin) regulates the proteome, lipidome, lipid metabolism and inflammatory profile of rat visceral adipose tissue

    Biochemical Pharmacology, Vol. 223

2023

  1. The lipidomic and inflammatory profiles of visceral and subcutaneous adipose tissues are distinctly regulated by the SGLT2 inhibitor empagliflozin in Zucker diabetic fatty rats

    Biomedicine and Pharmacotherapy, Vol. 161

2022

  1. Circulating miR-499a and miR-125b as Potential Predictors of Left Ventricular Ejection Fraction Improvement after Cardiac Resynchronization Therapy

    Cells, Vol. 11, Núm. 2

  2. Relaxin-2 as a Potential Biomarker in Cardiovascular Diseases

    Journal of Personalized Medicine, Vol. 12, Núm. 7

  3. Relaxin-2 plasma levels in atrial fibrillation are linked to inflammation and oxidative stress markers

    Scientific Reports, Vol. 12, Núm. 1

  4. Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models

    International Journal of Molecular Sciences, Vol. 23, Núm. 10

  5. The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile

    Frontiers in Pharmacology, Vol. 13

2021

  1. Relaxin has beneficial effects on liver lipidome and metabolic enzymes

    FASEB Journal, Vol. 35, Núm. 7

2020

  1. Adipokines and inflammation: Focus on cardiovascular diseases

    International Journal of Molecular Sciences, Vol. 21, Núm. 20, pp. 1-34